Related Experiment Videos
Manipulating expression of endogenous oncogenic proteins using an antisense oligonucleotide approach in prostate
Daqing Wu1, Ginger G Wescott, David M Terrian
1Department of Anatomy and Cell Biology, Brody School of Medicine at East Carolina University, Greenville, NC, USA.
Abstract:
It has been shown that antisense oligodeoxynucleotide (ODN) treatments provide an effective, specific approach to inhibiting the function of target proteins. Using this method, we have acquired additional evidence that protein kinase C-epsilon functions as an oncogenic protein in the progression of recurrent human prostate cancer. This chapter describes the use of antisense ODN to directly target cellular protein kinase C-epsilon as a potential chemotherapeutic agent for blocking the advance of prostatic adenocarcinoma to androgen-independence. Using Lipofectin as the carrier, phosphorothioate-modified antisense ODNs were transferred into prostate cancer cells with high efficiency, effectively inhibiting the expression of endogenous protein kinase C-epsilon and the androgen-independent (AI) proliferation of several independent human prostate cancer cell lines.
Insights
Antisense oligodeoxynucleotides (ODN) show promise in treating prostate cancer by inhibiting protein kinase C-epsilon. This approach effectively blocks cancer cell proliferation and progression to androgen-independence.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Antisense oligodeoxynucleotides (ODN) offer a specific method for inhibiting target protein function.
- Protein kinase C-epsilon has been implicated as an oncogenic protein in recurrent human prostate cancer progression.
Purpose of the Study:
- To investigate the use of antisense ODN to target protein kinase C-epsilon.
- To evaluate antisense ODN as a potential chemotherapeutic agent against prostate adenocarcinoma and androgen-independent progression.
Main Methods:
- Utilizing phosphorothioate-modified antisense ODNs delivered via Lipofectin.
- Introducing ODNs into human prostate cancer cell lines to inhibit endogenous protein kinase C-epsilon expression.
Main Results:
- High efficiency transfer of antisense ODNs into prostate cancer cells.
- Effective inhibition of protein kinase C-epsilon expression.
- Significant blockade of androgen-independent (AI) proliferation in multiple prostate cancer cell lines.
Conclusions:
- Antisense ODN targeting of protein kinase C-epsilon is a viable strategy for prostate cancer therapy.
- This method can prevent the progression of prostatic adenocarcinoma to an androgen-independent state.